AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11174772 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary CEA alone
Number of subjects: 10561
Study 11174772 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antiplatelet agents
Number of subjects: 10561
Study 11174772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative heparin
Number of subjects: 10561
Study 11174772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch angioplasty
Number of subjects: 10561
Study 11174772 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat procedures
Number of subjects: 10561
Study 11174772 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA combined with coronary artery bypass grafting
Number of subjects: 10561
Study 31344011 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-compression shorts at 6-15 mm Hg
Number of subjects: 12
Study 31344011 — intervention group
Group type: COMPARATOR
Intervention: Thigh-compression shorts at 0 mm Hg (control)
Number of subjects: 12
Study 30193809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ankle mobilization with movement
Number of subjects: 28
Study 30193809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ankle mobilization with movement with a 10° inclined board
Number of subjects: 28
Study 27096858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate supplement (12.5% carbohydrate, 400ml six hours and 200ml two hours before surgery)
Number of subjects: 27
Study 27096858 — intervention group
Group type: COMPARATOR
Intervention: Control group with fasting prescription 6-8 hours before surgery
Number of subjects: 27
Study 24450319 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose frequency (HDF) - five 1‐hr sessions per week
Number of subjects: 0
Study 24450319 — intervention group
Group type: COMPARATOR
Intervention: Low dose frequency (LDF) - one 1‐hr session per week
Number of subjects: 0
Study 23427390 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese spinal orthopedic manipulation (TCSOM), 5 treatments
Number of subjects: 210
Study 23427390 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide Dicetel (PBD)
Number of subjects: 210
Study 23427390 — intervention group
Group type: EXPERIMENTAL
Intervention: TCSOM
Number of subjects: 210
Study 20304982 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 80
Study 20304982 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 80
Study 16899479 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beclometasone
Number of subjects: 75
Study 16899479 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone on lymphocyte proliferation stimulated by PHA
Number of subjects: 75
Study 15177704 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of TSH
Number of subjects: 120
Study 15177704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of individuals with TSH levels suspect for thyroid disorder (n=2) or who were on thyroid replacement (n=3)
Number of subjects: 120
Study 15177704 — intervention group
Group type: EXPERIMENTAL
Intervention: Control for mood status
Number of subjects: 120
Study 15177704 — intervention group
Group type: EXPERIMENTAL
Intervention: No interaction between age and TSH on cognition
Number of subjects: 120
Study 11586012 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg elemental zinc
Number of subjects: 332
Study 11586012 — intervention group
Group type: COMPARATOR
Intervention: 100 mg minocycline
Number of subjects: 332
Study 9696082 — intervention group
Group type: COMPARATOR
Intervention: Standard differential-pressure valve
Number of subjects: 344
Study 9696082 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta valve (Medtronic PS Medical)
Number of subjects: 344
Study 9696082 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbis-Sigma valve (Cordis)
Number of subjects: 344
Study 7730892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 208
Study 7730892 — intervention group
Group type: EXPERIMENTAL
Intervention: Summated MAI
Number of subjects: 208
Study 2720725 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuart Prenatal tablet
Number of subjects: 17
Study 2720725 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuartnatal 1 + 1
Number of subjects: 17
Study 2720725 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna 1.60
Number of subjects: 17
Study 2720725 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuartnatal 1 + 1 and Materna 1.60
Number of subjects: 17
Study 29027602 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction information present
Number of subjects: 1161
Study 29027602 — intervention group
Group type: COMPARATOR
Intervention: Risk reduction information absent
Number of subjects: 1161
Study 29027602 — intervention group
Group type: EXPERIMENTAL
Intervention: No social comparison information
Number of subjects: 1161
Study 29027602 — intervention group
Group type: COMPARATOR
Intervention: Social comparison information present (higher than average risk)
Number of subjects: 1161
Study 29070027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic cycling exercise at 70% of the heart rate reserve [0.7 × (HRmax - HRrest)]
Number of subjects: 22
Study 26328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-EE (ethyl ester)
Number of subjects: 66
Study 26328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-TG (triglyceride)
Number of subjects: 66
Study 26328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 66
Study 26328782 — intervention group
Group type: COMPARATOR
Intervention: All groups (Fish oil-EE, Fish oil-TG, Krill oil)
Number of subjects: 66
Study 23211514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-nutrient drink (500 ml, 532 kcal)
Number of subjects: 60
Study 21998288 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 1209
Study 21998288 — intervention group
Group type: COMPARATOR
Intervention: Comparator agents
Number of subjects: 1209
Study 21998288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroides fragilis
Number of subjects: 1209
Study 21998288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroides thetaiotaomicron
Number of subjects: 1209
Study 21998288 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium species
Number of subjects: 1209
Study 18086493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation (single dose)
Number of subjects: 20
Study 18086493 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20
Study 18086493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg racemic albuterol after fluticasone pretreatment
Number of subjects: 20
Study 18086493 — intervention group
Group type: COMPARATOR
Intervention: Albuterol formulations after placebo or fluticasone pretreatment
Number of subjects: 20
Study 16130018 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical therapy (N=12)
Number of subjects: 21
Study 14574751 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed test
Number of subjects: 210
Study 14574751 — intervention group
Group type: COMPARATOR
Intervention: Computerized test
Number of subjects: 210
Study 14574751 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Number of subjects: 210
Study 10668942 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 57
Study 10668942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8674162 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (250, 500, 750, 1000, 1200 mg/m2) infused over 2 hours on days 1 and 2, with G-CSF 5 micrograms/kg per day starting on day 3 until WBC was > or = 10,000/microliters
Number of subjects: 21
Study 1898644 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus medical treatment
Number of subjects: 468
Study 1898644 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 468
Study 6344715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide plus low-dose prednisone
Number of subjects: 53
Study 6344715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azathioprine plus low-dose prednisone
Number of subjects: 53
Study 6344715 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 53
Study 30794084 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT+RT (Testosterone Replacement Therapy + Resistance Training)
Number of subjects: 22
Study 30794084 — intervention group
Group type: COMPARATOR
Intervention: TRT (Testosterone Replacement Therapy)
Number of subjects: 22
Study 28640845 — intervention group
Group type: COMPARATOR
Intervention: Instruction-only group (n = 262; issued with pre-scripted instructions on the low-sensitivity pregnancy test)
Number of subjects: 525
Study 28640845 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration group (n = 263; performed practice tests guided by lay health workers)
Number of subjects: 525
Study 26896232 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG) with sequential introduction of 6 allergenic foods: cow's milk, peanut, hard-boiled hen's egg, sesame, whitefish (cod), and wheat; continued breastfeeding.
Number of subjects: 1303
Study 26896232 — intervention group
Group type: COMPARATOR
Intervention: Standard introduction group following UK infant feeding recommendations of exclusive breastfeeding for around 6 months with no introduction of allergenic foods before 6 months of age.
Number of subjects: 1303
Study 26896232 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG)
Number of subjects: 1303
Study 26896232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1303
Study 25142305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000mg daily)
Number of subjects: 932
Study 25142305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 932
Study 22581994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² intravenously) as add-on therapy
Number of subjects: 31
Study 22581994 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and calcineurin inhibitors (standard treatment)
Number of subjects: 31
Study 19339061 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with allergic rhinitis
Number of subjects: 1368
Study 19339061 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1368
Study 19339061 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 1368
Study 19339061 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpets
Number of subjects: 1368
Study 19339061 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollution
Number of subjects: 1368
Study 19339061 — intervention group
Group type: EXPERIMENTAL
Intervention: Other factors (low birth weight, maternal age, parental education, gestational complications, tobacco smokers, pets, molds)
Number of subjects: 1368
Study 17445857 — intervention group
Group type: EXPERIMENTAL
Intervention: Two concurrent moving stimuli
Number of subjects: 0
Study 17445857 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving stimuli
Number of subjects: 0
Study 17445857 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash stimuli
Number of subjects: 0
Study 16087005 — intervention group
Group type: COMPARATOR
Intervention: Sandblasting (Group I)
Number of subjects: 40
Study 16087005 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser etching at 3.0 J/cm2 (Group II)
Number of subjects: 40
Study 16087005 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser etching at 4.0 J/cm2 (Group III)
Number of subjects: 40
Study 16087005 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser etching at 4.9 J/cm2 (Group IV)
Number of subjects: 40
Study 16087005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sandblasting and laser etching at 4.0 J/cm2 (Group V)
Number of subjects: 40
Study 12106575 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme consisting of four sessions
Number of subjects: 67
Study 12106575 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study 10798126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation 1.0 x 10(8) million viable spores/day/child for 15 days
Number of subjects: 30
Study 10798126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus supplementation 2.0 x 10(8) million viable spores/day/child for 90 days
Number of subjects: 30
Study 10798126 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 30
Study 7747375 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin 1 mg/kg orally daily until remission (max 3 months)
Number of subjects: 86
Study 7747375 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a 3 x 10(5) IU subcutaneously three times weekly plus isotretinoin 1 mg/kg orally daily until remission (max 8 weeks)
Number of subjects: 86
Study 2103760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg t.d.s.)
Number of subjects: 7
Study 2103760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7339223 — intervention group
Group type: COMPARATOR
Intervention: Continuous training at a heart rate of 140 b/min (C140)
Number of subjects: 24
Study 7339223 — intervention group
Group type: COMPARATOR
Intervention: Continuous training at a heart rate of 172 b/min (C172)
Number of subjects: 24
Study 7339223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training at a heart rate of 140 b/min (I140)
Number of subjects: 24
Study 7339223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training at a heart rate of 172 b/min (I172)
Number of subjects: 24
Study 31950481 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (1 ng/kg/min)
Number of subjects: 384
Study 31950481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of saline)
Number of subjects: 384
Study 29910795 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell/tumor antigen vaccine (ADCTA) in conjunction with concomitant chemoradiotherapy (CCRT) with temozolomide
Number of subjects: 47
Study 29910795 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without immunotherapy
Number of subjects: 47
Study 26750130 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV (procarbazine, CCNU, vincristine) chemotherapy following radiotherapy (RT)
Number of subjects: 0
Study 26750130 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 0
Study 26750130 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study 24625530 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-FTC
Number of subjects: 220
Study 24625530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 21963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation of tibia at 0.3g, 0.6g, and 1.2g at 30Hz
Number of subjects: 11
Study 21963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation of tibia
Number of subjects: 11
Study 21963319 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of mechanical oscillation
Number of subjects: 11
Study 20677726 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microm flap thickness
Number of subjects: 240
Study 20677726 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microm flap thickness
Number of subjects: 240
Study 20677726 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 microm flap thickness
Number of subjects: 240
Study 20677726 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 microm flap thickness
Number of subjects: 240
Study 18386581 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM therapy combined with radiotherapy
Number of subjects: 55
Study 18386581 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 55
Study 15989938 — intervention group
Group type: COMPARATOR
Intervention: Left TLE patients
Number of subjects: 124
Study 15989938 — intervention group
Group type: COMPARATOR
Intervention: Left TLE patients with lateral temporal lobe lesions
Number of subjects: 124
Study 15989938 — intervention group
Group type: COMPARATOR
Intervention: Left TLE patients with mesial temporal lobe lesions
Number of subjects: 124
Study 15989938 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic memory factor
Number of subjects: 124
Study 12602446 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg fexofenadine (F)
Number of subjects: 42
Study 12602446 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diphenhydramine (D)
Number of subjects: 42
Study 12602446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 42
Study 10982197 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release melatonin, 2 mg/day for 4 weeks
Number of subjects: 19
Study 10982197 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 19
Study 8828240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (6 sessions) in addition to usual methadone maintenance treatment
Number of subjects: 80
Study 8828240 — intervention group
Group type: COMPARATOR
Intervention: Usual methadone maintenance treatment only
Number of subjects: 80
Study 1349509 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of loratadine once daily
Number of subjects: 59
Study 1349509 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of hydroxyzine thrice daily
Number of subjects: 59
Study 1349509 — intervention group
Group type: COMPARATOR
Intervention: Placebo thrice daily
Number of subjects: 59
Study 1349509 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnolence or sedation
Number of subjects: 59
Study 3882583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate cream
Number of subjects: 28
Study 3882583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate sustained-release tablets
Number of subjects: 28
Study 3521531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene (Navane)
Number of subjects: 50
Study 3521531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30336580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index carbohydrate diet replacing saturated fatty acids (SFA)
Number of subjects: 389
Study 30336580 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) and high glycaemic index carbohydrates replacing saturated fatty acids (SFA)
Number of subjects: 389
Study 30336580 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) and low glycaemic index carbohydrates replacing saturated fatty acids (SFA)
Number of subjects: 389
Study 27072189 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS prompts
Number of subjects: 56
Study 27072189 — intervention group
Group type: COMPARATOR
Intervention: Historical control (no SMS prompts)
Number of subjects: 56
Study 24642828 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (5 mL/kg)
Number of subjects: 50
Study 24642828 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic saline (5 mL/kg)
Number of subjects: 50
Study 22613428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) plus patient-controlled analgesia (PCA)
Number of subjects: 60
Study 22613428 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus patient-controlled analgesia (PCA)
Number of subjects: 60
Study 20128535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral AcrySof ReSTOR Natural (SN60D3) intraocular lens (IOL) implantation
Number of subjects: 23
Study 18843564 — intervention group
Group type: EXPERIMENTAL
Intervention: Health intervention programme
Number of subjects: 82
Study 18843564 — intervention group
Group type: COMPARATOR
Intervention: Control programme with aesthetic content
Number of subjects: 82
Study 16394436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole 100 mg, two capsules twice daily for seven days a month for four months.
Number of subjects: 120
Study 16394436 — intervention group
Group type: COMPARATOR
Intervention: Oral terbinafine 250 mg, one tablet twice daily for seven days every month for four months.
Number of subjects: 120
Study 12927462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner fibre framework (sandblasted and silane coated)
Number of subjects: 0
Study 12927462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner composite layer (sandblasted and silane coated)
Number of subjects: 0
Study 12927462 — intervention group
Group type: COMPARATOR
Intervention: Control group (inner fibre framework, not sandblasted or silane coated)
Number of subjects: 0
Study 11218052 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 8881809 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 47
Study 8881809 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 47
Study 1404052 — intervention group
Group type: EXPERIMENTAL
Intervention: All dressings discarded after 5 days
Number of subjects: 33
Study 1404052 — intervention group
Group type: COMPARATOR
Intervention: Occlusive bandage continued for a further 2 weeks
Number of subjects: 33
Study 4009554 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplement with reduced amounts of calcium and magnesium
Number of subjects: 0
Study 4009554 — intervention group
Group type: COMPARATOR
Intervention: Two other prenatal supplements
Number of subjects: 0
Study 30156758 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-257 30 mg/kg subcutaneously every other week for 8 weeks
Number of subjects: 48
Study 30156758 — intervention group
Group type: COMPARATOR
Intervention: ABBV-257 (various doses: 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously)
Number of subjects: 48
Study 30156758 — intervention group
Group type: COMPARATOR
Intervention: ABBV-257 (single-dose study)
Number of subjects: 48
Study 30156758 — intervention group
Group type: COMPARATOR
Intervention: ABBV-257 (multiple-dose study)
Number of subjects: 48
Study 30156758 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-257
Number of subjects: 48
Study 30351407 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors (RASi)
Number of subjects: 2416
Study 30351407 — intervention group
Group type: COMPARATOR
Intervention: Non-renin-angiotensin system inhibitors (non-RASi)
Number of subjects: 2416